Beta Bionics Faces Securities Class Action Over iLet Safety Claims
News related to:Beta Bionics, Inc · 2 min read
Beta Bionics, Inc., a company developing automated insulin delivery systems, faces a securities class action lawsuit following a series of FDA compliance issues. The lawsuit, initiated by the National Shareholders Rights firm Hagens Berman, claims that Beta Bionics misled investors about the safety and regulatory status of its iLet device.
According to the lawsuit, Beta Bionics heavily promoted its iLet system as the most automated and user-friendly insulin delivery device on the market. The company assured investors that healthcare professionals were seeing positive results from their patients and becoming increasingly comfortable prescribing the iLet. However, the lawsuit alleges that Beta Bionics concealed thousands of safety complaints, including life-threatening hypoglycemic events, related to the iLet.
On October 28, 2025, Beta Bionics' management disclosed that the company had received a Form 483 from the FDA following an inspection of the iLet manufacturing process. The management downplayed the inspection, stating that it was "not unusual in our industry" and that the company was confident its new complaint handling system met regulatory expectations.
By February 24, 2026, the truth emerged. The FDA published a WARNING LETTER to CEO Saint, citing significant violations, including the company's failure to adequately analyze quality data, implement corrective actions for device malfunctions leading to serious adverse health outcomes, and report information to the FDA regarding deaths or serious injuries caused by the iLet. The letter highlighted that Beta Bionics had failed to report to the FDA information no later than 30 calendar days after receiving or becoming aware of such information.
The lawsuit alleges that Beta Bionics' statements to investors were misleading and that the company intentionally concealed critical safety information. Hagens Berman is investigating whether Beta Bionics may have intentionally misled investors by prioritizing revenues over patient safety.
The class action seeks to represent investors who purchased or otherwise acquired shares of Beta Bionics' common stock between July 30, 2025, and February 24, 2026. Lead plaintiff deadlines are set for November 3, 2026. Interested investors are encouraged to submit their losses to Hagens Berman.
Hagens Berman, a global plaintiffs' rights complex litigation firm, is leading the investigation.